Kite Pharma, Inc., a clinical-stage biotechnology company focusing on developing engineered autologous T cell therapy (eACT) products for cancer, announced the appointment of Rizwana F. Sproule, Ph.D., to the newly created position of Vice President, Regulatory Affairs.
According to a release, Dr. Sproule has over 16 years of experience in regulatory affairs for both biologics and small molecule therapeutics across multiple therapeutic areas. Her appointment is effective immediately.
Arie Belldegrun, M.D., Founder and Executive Chairman of the Board of Kite Pharma, commented, "Rizwana offers an impressive track record in guiding the regulatory process for well-recognized best- in-class therapies, and her expertise in working with international agencies FDA, EMA/CHMP, Health Canada, and PMDA at multiple levels will be critical to Kite's further advancement and planning. We are excited about the increasing momentum at Kite and are delighted to welcome Rizwana to our growing leadership team."
Prior to joining Kite, Dr. Sproule held senior positions at Amgen, including Executive Director, Therapeutic Area Head for Oncology Global Regulatory Affairs. In this position Dr. Sproule had global oversight of a diverse range of oncology therapeutics, including monoclonal antibodies, oncolytic viruses, bispecific single chain T-cell engager antibodies and small molecule agents. While at Amgen, she also served as the regulatory lead for the development of Vectibix and its companion diagnostic, and she led global filings and approvals for manufacturing changes across multiple products, including for Aranesp. Dr. Sproule began her career at SmithKline Beecham Pharmaceuticals.
((Comments on this story may be sent to firstname.lastname@example.org))